Fostriecin: A review of the preclinical data

Anti-Cancer Drugs

Volumn 8, Issue 5, 1997, Pages 413-418

  De Jong, R S ^a   De Vries, E G E ^a   Mulder, N H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antibiotics; DNA topoisomerase; Drug resistance; Fostriecin; Phosphoprotein phosphatases

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CARRIER PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); FOLIC ACID; FOSTRIECIN; PHOSPHOPROTEIN PHOSPHATASE;

ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DRUG MECHANISM; DRUG RESISTANCE; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

EID: 0030820773     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199706000-00001     Document Type: Review

References (45)

1. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996; 32A: 958-66.
2. Osheroff N, Zechiedrich E, Gale KC. Catalytic function of DNA topoisomerase II. Bioessays 1991; 13: 269-75.
3. Berger JM, Gamblin SJ, Harrison SC, Wang JC. Structure and mechanism of DNA topoisomerase II. Nature 1996; 379: 225-32.
4. Pommier Y, Leteurtre F, Fesen MR, et al. Cellular determinants of sensitivity and resistance to topoisomerase inhibitors. Cancer Invest 1994; 12: 530-42.
5. Cummings J, Smyth JF. DNA topoisomerase I and II as targets for rational design of new anticancer drugs. Ann Oncol 1993; 4: 533-43.
6. Tunac JB, Graham BD, Dobson WE. Novel antitumor agents CI-920, PD 113,270 and PD 113,271. I: taxonomy, fermentation and biological properties. J Antibiot 1983; 36: 1595-600.
7. Stampwala SS, Bunge RH, Hurley TR. Novel antitumor agents CI-920, PD 113,270 and PD 113,270. II: isolation and characterization. J Antibiot 1983; 36: 1601-5.
8. Hokanson GC, French JC. Novel antitumor agents CI-920, PD 113270 and PD 113271. III: structure determination. J Org Chem 1985; 50: 462-6.
9. Leopold WR, Shillis JL, Mertus AE, Nelson JM, Roberts BJ, Jackson RC. Anticancer activity of the structurally novel antibiotic CI-920 and its analogues. Cancer Res 1984; 44: 1928-32.
10. Jackson RC, Fry DW, Boritzki TJ, Roberts BJ, Hook KE, Leopold WR. The biochemical pharmacology of CI-920, a structurally novel antibiotic with antileukemic activity. Adv Enzyme Regul 1985; 23: 193-215.
11. Fry DW, Besserer JA, Boritzki TJ. Transport of the antitumor antibiotic CI-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res 1984; 44: 3366-70.
12. Mamber SW, Okasinski WG, Pinter CD, Tunac JB. Antimycotic effects of the novel antitumor agents fostriecin (CI-920), PD 113,270 and PD 113,271. J Antibiot 1986; 39: 1467-72.
13. Fry DW, Boritzki TJ, Jackson RC. Studies on the biochemical mechanism of the novel antitumor agent, CI-920. Cancer Chemother Pharmacol 1984; 13: 171-5.
14. Gedik CM, Collins AR. Comparison of effects of fostriecin, novobiocin, and camptothecin, inhibitors of DNA topoisomerases, on DNA replication and repair in human cells. Nucleic Acids Res 1990; 18: 1007-13.
15. Boritzki TJ, Wolfard TS, Besserer JA, Jackson RC, Fry DW. Inhibition of type II topoisomerase by fostriecin. Biochem Pharmacol 1988; 37: 4063-8.
16. Chen M, Beck WT. Teniposide-resistant CEM cells, which express mutant DNA topoisomerase II alpha, when treated with non-complex-stabilizing inhibitors of the enzyme, display no cross-resistance and reveal aberrant functions of the mutant enzyme. Cancer Res 1993; 53: 5946-53.
17. Fattman CL, Allan WP, Hasinoff BB, Yalowich JC. Collateral sensitivity to the bisdioxopiperazine dexrazoxan (ICRF-187) in etoposide (VP-16)-resistant human leukemia K562 cells. Biochem Pharmacol 1996; 52: 635-42.
18. Frosina G, Rossi O. Effect of topoisomerase poisoning by antitumor drugs VM 26, fostriecin and camptothecin on DNA repair replication by mammalian cell extracts. Carcinogenesis 1992; 13: 1371-7.
19. de Jong S, Zijlstra JG, Mulder NH, de Vries EGE. Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance. Cancer Chemother Pharmacol 1991; 28: 461-4.
20. 4. Br J Cancer 1996; 74: 1896-76.
21. Ferguson PJ, Fisher MH, Stephenson J, Li D, Zhou B, Cheng Y. Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res 1988; 48: 5956-64.
22. Roberge M, Tudan C, Hung SMF, Harder KW, Jirik FR, Anderson H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res 1994; 54: 6115-21.
23. Pines J. Cyclins and cyclin dependent kinases: theme and variations. Adv Cancer Res 1995; 66: 181-212.
24. Guo XW, Thng JPH, Swank RA, et al. Chromosome condensation induced by fostriecin does not require p34(cdc2) kinase activity and histone hi hyperphosphorylation, but is associated with enhanced histone h2a and h3 phosphorylation. EMBO J 1995; 14: 976-85.
25. Ho DT, Roberge M. The antitumor drug fostriecin induces vimentin hyperphosphorylation and intermediate filament reorganization. Carcinogenesis 1996; 17: 967-72.
26. Hotz MA, Del Bino G, Lassota P, Traganos F, Darzynkiewicz Z. Cytostatic and cytotoxic effects of fostriecin on human promyelocytic HL-60 and lymphocytic MOLT-4 leukemic cells. Cancer Res 1992; 52: 1530-5.
27. Hotz MA, Traganos F, Darzynkiewicz Z. Changes in nuclear chromatin related to apoptosis or necrosis induced by the DNA topoisomerase II inhibitor fostriecin in MOLT-4 and HL-60 cells are revealed by altered DNA sensitivity to denaturation. Exp Cell Res 1992; 201: 184-91.
28. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res 1993; 53: 1945-51.
29. Gorczyca W, Bigman K, Mittelman A, et al. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia 1993; 7: 659-70.
30. Gorczyca W, Gong J, Ardelt B, Traganos F, Darzynkeiwicz Z. The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res 1993; 53: 3186-92.
31. Spinella MJ, Brigle KE, Sierra EE, Goldman ID. Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. J Biol Chem 1995; 270: 7842-9.
32. Scheithauer W, Von Hoff DD, Clark GM, Shillis JL, Elslager EF. In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay. Eur J Cancer Clin Oncol 1986; 22: 921-6.
33. Howard CT, Leopold WR, Sebolt JS. Characterization of a murine leukemia cell line selected for in vivo resistance to fostriecin (phosphotrienin). Proc Am Ass Cancer Res 1985; 26: 339 (abstr 1336).
34. Baguley BC, Calveley SB, Crowe KK, Fray LM, O'Rourke SA, Smith GP Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice. Eur J Cancer Clin Oncol 1989; 25: 263-9.
35. Rao KR, Fritz-Niggli H. Response of murine small intestine to combined treatment with fostriecin. Br J Radiol 1990; 63: 286-9.
36. Susick RL, Jr., Hawkins KL, Pegg DG. Preclinical toxicological evaluation of fostriecin, a novel anticancer antibiotic, in rats. Fundam Appl Toxicol 1990; 15: 258-69.
37. Pillon L, Moore MJ, Thiessen JJ. Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay. Ther Drug Monit 1994; 16: 186-90.
38. Du DL, Volpe DA, Grieshaber CK, Murphy MJ. Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro. Invest New Drugs 1991; 9: 149-57.
39. Francis GE, Tejedor MC, Berney JJ, Chresta CM, Delgado C, Patel P. Effects of DNA topoisomerase II inhibitors on human bone marrow progenitor cells. Leukemia 1994; 8: 121-8.
40. De Jong RS, Mulder NH, Uges DRA, van der Graaf WTA, Meijer S, de Vries EGE. Phase I clinical and pharmacokinetic study of 5 days 1 hour infusion of fostriecin in patients with solid tumors. Ann Oncol 1996; 7(suppl 1): 100 (abstr 351).
41. Antony A. The biological chemistry of folate receptors. Blood 1992; 79: 2807-20.
42. Said HM, Nguyen TT, Dyer DL, Cowan KH, Rubin SA. Intestinal folate transport: identification of a cDNA involved in folate transport and the functional expression and distribution of its mRNA. Biochim Biophys Acta 1996; 1281: 164-72.
43. Schilsky RL, Ramirez J, Wilson K, et al. Phase I clinical and pharmacologic study of fostriecin in patients with advanced cancer. Proc Am Soc Clin Oncol 1994; 13: 132 (abstr 321).
44. Thenault R, Schmidt S, Newman RA, Raber M, Hortobagyi G. Phase I clinical and pharmacokinetic evaluation of fostriecin (CI-920). Proc Am Soc Clin Oncol 1994; 13: 165 (abstr 455).
45. Moore MJ, Erlichman C, Pillon L, Manzo J, Thiessen JJ, Eisenhauer E. A phase I clinical and pharmacokinetic study of fostriecin in a daily X 5 schedule. Proc Am Soc Clin Oncol 1995; 14: 474 (abstr 1537).